Comparative impact of antiviral therapies on postoperative recurrence risk in patients with hepatitis B virus-related hepatocellular carcinoma

Table 1 Baseline characteristics of hepatitis B virus-related hepatocellular cancer patients, n (%)

Characteristics	Overall (n = 100)	ETV group (n = 50)	TDF group (n = 50)	P value
Age (years), median (interquartile range)	61 (52-69)	60 (52-67)	62 (54-69)	0.308
Gender (male)	84 (84.0)	42 (84.0)	42 (84.0)	1.000
HBeAg	22 (22.0)	10 (20.0)	12 (24.0)	0.751
HBV-DNA (> 103 IU/mL)	68 (68.0)	35 (70.0)	33 (66.0)	0.236
Liver cirrhosis	58 (58.0)	28 (56.0)	30 (60.0)	0.635
Tumor size (cm)	3.0 (2.1, 4.3)	3.0 (2.2, 4.3)	2.9 (2.1, 3.8)	0.381
MVI	39 (39.0)	19 (38.0)	20 (40.0)	0.942
Capsular invasion	51 (51.0)	25 (50.0)	26 (52.0)	0.576
Satellite nodules	15 (15.0)	8 (16.0)	7 (14.0)	0.263
Tumor differentiation				0.759
Well	3 (3.0)	2 (4.0)	1 (2.0)
Moderate	49 (49.0)	25 (50.0)	24 (48.0)
Poorly	48 (48.0)	23 (46.0)	25 (50.0)
PVTT	25 (25.0)	12 (24.0)	13 (26.0)	0.246
AFP (> 400 ng/mL)	51 (51.0)	26 (52.0)	25 (50.0)	0.803
TBIL (> 28 μmol/L)	3 (3.0)	2 (4.0)	1 (2.0)	0.237
ALT (> 40 U/L)	47 (47.0)	23 (46.0)	24 (48.0)	0.345
AST (> 40 U/L)	60 (60.0)	31 (62.0)	29 (58.0)	0.549
ALB (> 40 g/L)	69 (69.0)	34 (68.0)	35 (70.0)	0.296
Follow-up duration, months	29 (12-60)	28 (12-47)	31 (12-60)	0.677
BCLC stage				0.755
0	16 (16.0)	7 (14.0)	9 (18.0)
A	61 (61.0)	31 (62.0)	30 (60.0)
B	23 (23.0)	12 (24.0)	11 (22.0)
Child-Pugh score				0.726
A	45 (45.0)	23 (46.0)	22 (44.0)
B	55 (55.0)	27 (54.0)	28 (56)
ECOG score				0.271
0-1	58 (58.0)	28 (56.0)	30 (60.0)
2	42 (42.0)	22 (44.0)	20 (40.0)

The statistical comparison was performed by Mann-Whitney U Test or χ² test. Significant difference at P < 0.05. AFP: Α-fetoprotein; ALB: Albumin; ALT: Alanine aminotransferase; BCLC: Barcelona Clinic Liver Cancer; ECOG: Eastern Cooperative Oncology Group; HBV: Hepatitis B virus; MVI: Microvascular invasion; PVTT: Portal vein tumor thrombus.